Cell Surface Iodination, Solubilization, and Immunoprecipitation. The procedure of Kessler (23) 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-P.A GE).
The procedure of Laemli (25) as modified by Cullen and Schwartz (24) was employed. Samples were reduced with 2-mercaptoethanoi in the presence of SDS and applied to 10% polyaerylamide gels containing 0.1% SDS. Electrophoresis was carried out at a current of 5 mA/gel.
Antisera. Anti-Lyb5.1 serum was prepared according to the procedure of Ahmed et al. (13) .
Briefly, hyperimmune C57BL/6 anti DBA/2 spleen cell antiserum was extensively absorbed with DBA/2 thymocytes until it had no anti-H-2 d activity. The antiserum was then absorbed with spleen cells from B-cell defective (CBA/N X DBA/2)F1 male mice until it had no cytotoxicity against the same cells. At this stage the antiserum still had an ability to kill 20-25% of the spleen cells from (CBA/N X DBA/2)F1 female mice or from DBA/2 mice and usually had cytotoxic titers of 1:16 to 1:32. All strains that are negative in this cytotoxicity test are referred to as Lyb5.1 negative strains, because it is not known if there are more than two allelic forms of Lyb 5.
Control antiserum was prepared by absorbing anti-Lyb5.1 serum with spleen cells from DBA/2 mice until it had no cytotoxicity against the same cells. Absorptions were carried out by addition of the antiserum to packed spleen cells and incubation at 4°C on rotary shaker for 1 h. All antisera were deaggregated just before use by ultracentrifugation at 130,000 g for 30 min in an airfuge (Beckman Instruments Inc., Cedar Grove, N. J.).
Rabbit anti-mouse K used in immunoprecipitation studies was a generous gift from Dr. Rose Mage (Laboratory of Immunology; NIAID, NIH). C3H/HeJ anti-CBA/J and CBA/J anti-C3H/HeJ sera were kindly provided by Dr. D. H. Sachs (Immunology Branch, NCI, NIH). These sera had cytotoxic titers of at least 1:64.
Cytotoxic Assay. 2.5 × 105 spleen cells depleted of erythrocytes were incubated with 50 #1 of antiserum diluted in 50 #1 of RPMI-1640 + 5% fetal calf serum in a microtiter plate at 4°C. After 1 h the plate was centrifuged at 800 g for 10 min and the supernate was discarded. Cells were incubated with 100 #1 of a 1:10 dilution of rabbit complement at 37°C for 30 min. The rabbit serum used as complement source had been screened for low background killing. The viability of the cells was tested by their ability to exclude trypan blue. Table I . The PFC responses to TNP-Ficoll were inhibited by more than 80% while there was little or no effect on the PFC response to this concentration of TNP-BA. cantly inhibited (Table II) . Responses to TNP-BA were not blocked in either strain. Summary data from experiments with several other Lyb 5.1-positive and negative strains are included in Table II . These data demonstrate that the responses of Lyb 5.1 negative strains to TNP-Ficoll were not affected by this antiserum. Furthermore, the responses to TNP-Ficoll by Lyb 5.1 positive-strains listed in Table II were inhibited to approximately the same degree as the response of DBA/2 mice. This includes mice which are heterozygous for Lyb 5.1.
Results

Effect of
Specificity of the Inhibition of Responses to TNP-Ficoll by
As an additional control for the significance of the blocking effect, we have tested another B-cell alloantiserum, anti-LyM 1 (CBA/J anti-C3H/HeJ) serum (26) in our 
+ -system and found that this serum had no inhibitory effect on the responses to either TNP-Ficoll or TNP-BA (Table III) . This suggests that the inhibition caused by antiLyb 5 is not a simple consequence of the binding of antibody to any membrane antigen of B lymphocytes. A detailed strain distribution of the cytotoxic and blocking activities of anti-Lyb 5.1 serum is presented in Table IV . The failure of anti-Lyb 5.1 serum to block responses of AL/N lymphocytes despite its capacity to lyse these cells provides initial evidence that the blocking antibodies and the cytotoxic antibodies may be directed against distinct alloantigens. This will be discussed in more detail later and in a subsequent paperfl For clarity, we will refer to the ability of anti-Lyb 5.1 serum to selectively inhibit responses to TNP-Ficoll as its blocking activity.
Susceptibility of PFC Responses to Various TI-1 and TI-2 Antigens to Inhibition by Anti-Lyb 5.1 Serum.
We observed that the extent of inhibition by anti-Lyb 5 serum was approximately the same, over a wide range of concentrations (10-2-10 -5 #g/ml) of TNP-Fieoll (Fig. 1) . Similarly, this antiserum inhibited the PFC responses to another TI-2 antigen, TNP-dextran, at all antigen concentrations tested (Fig. 2) . In contrast, the effect of anti-Lyb 5.1 serum on PFC responses to TNP-BA was dependent on the concentration of the antigen used (Table V) . At the concentration of TNP-BA (Table VI) . PC-BA belongs to the TI-2 class of antigens since the mice with CBA/N immune defect do not respond to phosphorylcholine on any carrier including BA (27) . Thus, the responses to the three TI-2 antigens tested are susceptible to inhibition by anti-Lyb 5.1 serum. Responses to optimal concentrations of two TI-1 antigens are not inhibited, although anti-Lyb 5.1 serum does diminish the response to a low concentration of TNP-BA.
Timing of Addition of Anti-Lyb 5.1 Serum to the Cell Cultures.
As a preliminary step in the analysis of the mechanism by which anti-Lyb 5.1 serum inhibited B cell responses, we wished to know when the antiserum had to be added to obtain inhibition. To test this we added anti-Lyb 5.1 or control serum to the culture at different times after the addition of TNP-FicoI1. Results of one such experiment are presented in Fig. 3 . AntiLyb 5.1 caused significant inhibition when added as late as 14 h after initiation of culture; when added at later times, little or no inhibition was observed. The loss of susceptibility to inhibition may be due either to a loss of the Lyb 5.1 antigen from the Precipitates were reduced by boiling in 5% 2-mercaptoethanol and 2% SDS and were subjected to electrophoresis in 10% polyacrylamide gels with 0.1% SDS. 2-mm slices were cut and the radioactivity was measured.
cell surface or because the Lyb 5.1 determinants have no further role in the events that lead to maturation of B cells to PFC.
Nature of Cell Surface Molecules Recognized by Anti-Lyb 5.1 Serum. It has been shown
previously that an alloanti-~ serum also can inhibit in vitro antibody responses to TNP-Ficoll (28) . Spleen cells from CBA/N or (CBA/N × DBA/2)F1 male mice have an sIgD to sIgM ratio which is approximately ~/s that of spleen cells from normal mice (9) . Furthermore, Lyb 5-negative cells from normal adult mice have a surface Ig phenotype similar to that of CBA/N cells, i.e, sIgM > sIgD (13) . Hence it is a formal possibility that C57BL/6 anti-DBA/2 serum contains anti-8 antibody and that absorption with (CBA/N × DBA/2)Fa male spleen cells which may be low in sIgD density could have failed to completely remove anti-8 activity. To test this possibility, cells were surface labeled with 125I and the solubilized membrane proteins were subjected to immunoprecipitation with anti-Lyb 5.1 serum and S. aureus. The resultant precipitates were dissolved in 2% SDS and were analyzed on SDS-PAGE as described. This finding suggested that the inhibitory and cytotoxic activities of anti-Lyb 5.1 serum might be due to two different specificities present in one antiserum. In a subsequent paper 2 we show that these two activities (blocking and cytotoxicity) segregate independently in the mice from the backcross (C57BL/6 × DBA/2) × C57BL/6. Thus the cytotoxic and blocking activities of this alloantiserum are due to recognition of two different cell surface determinants which are encoded by unlinked genes.
For the sake of clarity in this discussion, we will refer to the specific antigen recognized by the blocking activity of this antiserum as Lyb 7.1 as opposed to Lyb 5.1 which was defined by the cytotoxic activity of the antiserum. In the following discussion, any reference to anti-Lyb 7.1 is only to this blocking activity present in the antioLyb 5.1 serum since all the experiments reported in this paper make use of antiLyb 5.1 serum. Anti-Lyb 7.1 activity is present in an antiserum that has been extensively absorbed with spleen cells from the (CBA/N X DBA/2)F1 male mice, strongly suggesting that Lyb 7.1 is also present only on a subset of B lymphocytes that are absent from mice with the CBA/N defect. Since there are no Lyb 5 + cells in CBA/N mice, it is likely that Lyb 7 is present exclusively on Lyb 5 + B cells. The designation Lyb 7.1 is a preliminary one until decisive studies on tissue distribution are completed.
In vitro response to TI-2 antigens are always significantly suppressed by anti-Lyb 7.1, but the inhibition was never total, the average inhibition being 62%. It is conceivable that this reflects a low titer of the antibody, especially since the inhibition falls off rapidly at greater dilution (data not shown). However, since similar results were obtained with many different batches of the antiserum, it is formally possible that there is further heterogeneity among the B lymphocytes that respond to TI-2 antigens. At present we are making efforts to produce these antibodies in higher titers by alternative approaches.
Although the anti-TNP antibody response to optimal concentrations of TNP-BA is not suppressed by anti-Lyb 7.1 antibodies, there is significant inhibition of responses to lower concentrations of this antigen. As mentioned above, mice with the CBA/N defect respond poorly to such low doses of TNP-BA while giving normal responses to optimal concentrations of this antigen. One interpretation of this result is that low concentrations of TNP-BA stimulate only Lyb 7 + cells and the responses of such cells are inhibited by anti-Lyb 7.1 serum. It is likely that both Lyb 7 + and Lyb 7-cells are involved in responses to high doses of TNP-BA and the failure to observe any inhibition at these concentrations may be the result of a relative insensitivity of the present culture system to changes in precursor frequency. One prediction of this hypothesis is that anti-Lyb 7.1 activity will inhibit responses of Lyb 7 + cells to any antigen. An alternative possibility is that Lyb 7 + cells are involved in responses of adult mice to TNP-BA at both high and low doses but that only the responses to low concentrations are susceptible to inhibition by anti-Lyb 7.1. This issue can be resolved by an analysis of the effect of anti-Lyb 7.1 serum on both precursor frequency and burst size in responses to high and low concentrations of TI-1 antigens.
Our experiments do not address directly the question of the mechanism of the inhibition of responses to TI-2 antigens by anti-Lyb 7.1 antibodies. Since two alloantisera that have been tested, namely anti-8 (28) and anti-Lyb 7.1, both inhibit the responses to TNP-Ficoll, it is conceivable that a perturbation of the cell membrane due to interaction of any antiserum with a cell surface component may inhibit the response of B cells to this class of antigens. The inability of CBA/J anti-C3H/HeJ serum, which is cytotoxic for B cells (26) , to cause any inhibition of the responses to TNP-Ficoll constitutes strong evidence against this possibility. Similarly as will be shown subsequently, 2 anti-Lyb 5.1 serum fails to inhibit responses to Lyb 5.1 +, Lyb 7.1-backcross mice.
Another explanation of the inhibition is that binding of anti-Lyb 7.1 to Lyb 7 molecules on the cell surface stericaliy inhibits any effective interaction of antigen with the sIg receptors or some mitogen receptors (29) . Since the responses of spleen cells from an animal homozygous or heterozygous for Lyb 7 are equally sensitive to inhibition, 2 such a mechanism for anti-Lyb 7.1 action seems unlikely. This argument presumes that in the heterozygous mice, half of the Lyb 7 molecules remain unoccupied by the antibodies directed against the Lyb 7.1 determinant and that these molecules could be sufficient for the activation of the B lymphocytes. The equivalent susceptibility of homozygous and heterozygous cells seems more consistent with the concept that interaction of anti-Lyb 7.1 antibodies with Lyb 7.1 molecules may deliver an off signal to the cell and thus lead to inhibition of responses of Lyb 7 + B cells. Indeed, Lyb 7 may be a site through which suppression is mediated in vivo and inhibition by anti-Lyb 7.1 may be analogous to a physiological process.
It is interesting to note that an alloanti-8 serum also selectively inhibits responses to TI-2 antigens (28). The characteristics of inhibition by anti-Lyb 7.1 and anti-8 are similar but the action of anti-Lyb 7.1 is not due to its contamination with anti-8 antibody. This is shown both by analysis of membrane proteins precipitated by antiLyb 7.1 and by genetic studies which show a segregation of genes for Lyb 7 and 8. 2
Finally, anti-Lyb 3, which is similar to anti-Lyb 5 to the extent that it defines an antigen present only on a subset of B lymphocytes, also has some functional properties (30) . This antiserum has been shown to substitute for T cell help in vivo under certain conditions. Although anti-Lyb 5 serum could contain anti-Lyb 3-like activity, no functional evidence of such activity was seen in the present in vitro experiments. However, it is formally possible that the activation effects of anti-Lyb 3 and the blocking effects of anti-Lyb 7 simply reflect different consequences of the same interaction, dictated by the precise conditions in which they occur.
Summary
Lyb 5 is a B-cell alloantigen which is expressed on 50-60% of B cells. It was defined originally on the basis of cytotoxicity. We have described a new reactivity within the anti-Lyb 5 serum on the basis of selective inhibition of antibody responses in vitro by this antiserum in the absence of complement. This inhibitory activity of anti-Lyb 5.1 serum appears to be due to recognition of antigenic determinants different from the prototype antigens detected in the cytotoxicity assay.
Anti-Lyb 5 serum incorporated into spleen cell cultures selectively inhibits antibody responses to a class of thymus-independent antigens CFI-2) previously characterized by their failure to elicit antibody formation in immature mice or in the defective CBA/N strain. Responses to optimal concentrations of TI-1 antigens, which can induce antibody synthesis in these mice, are unaffected by the addition of anti-Lyb 5.1 serum. The B-cell alloantigen defined by this functional assay is designated tentatively Lyb 7 and it is shown to be distinct from cell surface immunoglobulins. Lyb 7 appears to have a role in the activation of B lymphocytes by the TI-2 class of thymus-independent antigens.
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